This post was originally published on this site
Indeed, the stock has gained 20.7% year-to-date to close yesterday’s trading session at $446.39.
But while DXCM is a dominant player in the CGM market, it faces stiff competition from other key players that are making significant headway in the continuous glucose monitoring space. And, although the company reported better-than-expected first quarter results, the stock’s stretched valuation could make investors nervous.
